Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies
- 24 May 2021
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 19 (5) , 625-634
Abstract
The arrival of precision oncology is challenging the evidence standards under which technologies are evaluated for regulatory approval as well as for health technology assessment (HTA) purposes. Several key concepts are discussed to highlight the source of the challenges in evaluating these products, particularly those impacting the HTA of histology-independent therapies. These include the basket trial design, high uncertainty in (potentially substantial) benefits for histology-independent therapies, and the inability to identify and quantify benefits of standard of care in daily practice when the biomarker is not currently used in practice. There is little precedent for a technology with the unique mixture of challenges for HTA of histology-independent therapies and they will be evaluated using standard HTA, as there currently is no evidence suggesting the standard HTA framework is not appropriate. A number of questions proposed to help guide HTA bodies when assessing the appropriateness of local processes to optimally evaluate histology-independent therapies. Pragmatic solutions are further proposed to decrease uncertainty in the benefits of histology independent therapies as well as fill gaps in comparative evidence. The proposed solutions ensure a consistent and streamlined approach to evaluation across histology-independent products, although with varying strengths and limitations. Alongside these solutions, sponsors should engage early with HTA bodies/payers and regulatory agencies through parallel/joint scientific advice to facilitate the integration of both regulatory and HTA perspectives into one clinical development programme, potentially reconciling evidence requirements.Keywords
Funding Information
- Bayer Corporation (Medical Writing Support)
This publication has 30 references indexed in Scilit:
- Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic TargetsCancers, 2019
- Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung CancerOncoTargets and Therapy, 2019
- In silico signaling modeling to understand cancer pathways and treatment responsesBriefings in Bioinformatics, 2019
- The Future of Precision Medicine: Potential Impacts for Health Technology AssessmentPharmacoEconomics, 2018
- Precision medicine becomes reality—tumor type‐agnostic therapyCancer Communications, 2018
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the IndicationNew England Journal of Medicine, 2017
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Implementing Genome-Driven OncologyCell, 2017
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014BMJ Open, 2016
- Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical TrialsThe Oncologist, 2016